Five Things the Women’s Health Initiative Got Wrong — and What We Know Now

The Women’s Health Initiative changed hormone therapy practice overnight. When the combined estrogen-progestin arm was halted in July 2002, the headlines were unambiguous: hormone therapy causes breast cancer, heart attacks, and strokes. Millions of women discontinued their prescriptions. Millions more were never offered therapy. An entire generation of physicians was trained to approach hormone therapy with caution bordering on avoidance.

Twenty-four years later, the evidence has matured considerably. The WHI was an important study. It was also a deeply flawed one, and the conclusions drawn from it were applied far more broadly than the data supports.

1. The Hormones Tested Are Not the Hormones Used Today

The WHI combined arm used oral conjugated equine estrogens (Premarin) and medroxyprogesterone acetate (Provera). Neither is bioidentical.

Conjugated equine estrogens are derived from pregnant horse urine and contain multiple estrogen compounds, several of which are not found in the human body. Medroxyprogesterone acetate is a synthetic progestin with off-target activity on androgen and glucocorticoid receptors, and in experimental models it opposes the cardioprotective and anti-inflammatory actions of estradiol.¹

Modern bioidentical hormone therapy uses estradiol (molecularly identical to human estrogen) and micronized progesterone (molecularly identical to human progesterone). The metabolic behaviour, receptor binding, and safety profile of these molecules differ from the ones the WHI tested.^{2, 3}

Applying the WHI’s findings to bioidentical hormone therapy is a category error. The molecules are different. The data is not transferable.

2. The Population Studied Was the Wrong Age

The average age of WHI participants at enrollment was 63. Many were 10 to 20 years past menopause. The study was designed to test whether hormone therapy could prevent chronic disease in older postmenopausal women, not whether it could support women through the menopausal transition.

This matters because the biological response to hormones changes with time since menopause. Vascular endothelium that has been estrogen-deprived for 15 years responds differently to estrogen than endothelium that has been deprived for 2 years. The “timing hypothesis,” supported by subsequent analyses including the WHI’s own age-stratified data,⁴ indicates that women who initiate hormone therapy within 10 years of menopause or before age 60 tend to have more favourable cardiovascular outcomes than women who start later.^{5, 6}

The WHI’s headline results were driven by the older cohort. Applying those results to a 51-year-old woman entering menopause is not supported by the study’s own subgroup analyses.

3. The Delivery Route — and the Molecule — Matter

The WHI used oral conjugated equine estrogens exclusively. Two features of that choice drive its thrombotic signal, and neither is intrinsic to estradiol.

The first is the route. Oral estrogens undergo first-pass hepatic metabolism, which increases the liver’s production of clotting factors (particularly factor VII and fibrinogen), CRP, and SHBG. Transdermal estradiol bypasses the liver entirely and largely avoids these procoagulant effects. The French ESTHER case-control study, published in Circulation in 2007, found that transdermal estrogen at standard doses was not associated with increased venous thromboembolism risk, while oral estrogen was.⁷ A 2008 systematic review and meta-analysis in the British Medical Journal reached the same conclusion.⁸

The second is the molecule. Even by the oral route, estradiol is not equivalent to conjugated equine estrogens. Premarin’s non-human estrogen fractions amplify the hepatic procoagulant response beyond what estradiol produces. A population-based analysis in JAMA Internal Medicine found that oral conjugated equine estrogens carried roughly double the venous thrombosis risk of oral estradiol, with a parallel signal for myocardial infarction.⁹ The large BMJ QResearch–CPRD study confirmed the same ordering: among oral preparations, estradiol carried a lower thromboembolism risk than conjugated equine estrogens, and transdermal preparations carried no measurable excess risk at all.¹⁰

The WHI’s cardiovascular and thrombotic findings belong to a specific combination — an oral route and a non-bioidentical molecule. The lowest-risk path, transdermal bioidentical estradiol, is precisely the one the study never tested.

4. The Progestin Was the Problem for Breast Cancer

The WHI had two arms. The combined estrogen-plus-progestin arm showed a modest increase in breast cancer incidence. The estrogen-only arm, in women who had undergone hysterectomy, showed a decrease in breast cancer incidence that persisted through long-term follow-up.¹¹

This finding isolates medroxyprogesterone acetate as the likely driver of the breast cancer risk. The French E3N cohort study, following over 80,000 women, confirmed that estrogen combined with bioidentical micronized progesterone did not increase breast cancer risk, while estrogen combined with synthetic progestins did.¹²

The WHI’s breast cancer finding is a medroxyprogesterone acetate finding, not a progesterone finding. Treating all progestogenic compounds as equivalent ignores the receptor pharmacology that explains the divergence.

5. The Absolute Risk Was Small, but the Communication Was Alarming

The WHI reported its results as relative risk increases, which produced alarming-sounding numbers. The absolute risk increase in breast cancer was 8 additional cases per 10,000 women per year, or 0.08 percent. The absolute risk increase in coronary events was 7 additional cases per 10,000 women per year.¹³

These are not trivial numbers at a population level. But they are small numbers at an individual level, and they must be weighed against the benefits of therapy (reduced fractures, reduced colorectal cancer, improved quality of life) and against the specific hormones, route, and timing that the individual patient would use.

The media coverage of the WHI communicated danger without nuance. The medical community responded with withdrawal rather than refinement. Women who would have benefited from appropriately prescribed, bioidentical, transdermal hormone therapy were denied it on the basis of a study that used different hormones, in an older population, through a riskier route.

What We Know Now

The evidence accumulated since 2002 supports a more refined position.

Hormone therapy initiated within 10 years of menopause, using transdermal bioidentical estradiol and micronized progesterone, at physiological doses, with appropriate monitoring, has a favourable risk-benefit profile for symptomatic women.

The cardiovascular data is reassuring when therapy is started early and delivered transdermally. The breast cancer data is reassuring when bioidentical progesterone is used instead of synthetic progestins. The bone, cognitive, and quality-of-life benefits are well documented.

The Endocrine Society, the North American Menopause Society, the International Menopause Society, and the British Menopause Society have all published updated position statements reflecting this more nuanced understanding.

What This Means for Patients

If you have been told that hormone therapy is dangerous based on the WHI, you have received an incomplete interpretation of the evidence.

The relevant questions are: What type of hormone? What route of delivery? At what age and time since menopause? What are your individual risk factors? What are the expected benefits for your specific symptom profile? How will hormone optimization affect your metabolic phenotype—your body composition, mitochondrial capacity, insulin sensitivity, and disease risk across systems?

A physician who can answer these questions with specificity, citing the distinction between synthetic and bioidentical hormones, between oral and transdermal delivery, and between the 2002 data and the subsequent two decades of research, is practicing evidence-informed medicine. That physician should also be measuring the systemic consequences of hormonal deficiency: the shift toward visceral adiposity, the decline in metabolic capacity, the reduction in tissue quality and resilience that untreated hormonal decline produces.

The WHI asked an important question. The answer it provided was specific to the hormones, population, and route it tested. Generalizing that answer to all hormone therapy, for all women, at all ages, was the error. Treating all untreated hormonal deficiency as safer than measured hormone replacement is another error. Correcting both is long overdue.

Continue Reading

If you found this useful, these related articles may deepen your understanding:

• Hormone Therapy and Breast Cancer Risk
• BHRT vs. Conventional HRT
• Why ‘Age-Appropriate’ Hormone Levels Are Flawed

References

1. Booth EA, et al. Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17β-estradiol. Am J Physiol Heart Circ Physiol. 2007. PMID: 17434982
2. Fitzpatrick LA, et al. Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril. 1999. PMID: 10519605
3. Campagnoli C, et al. Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol. 2005. PMID: 16249080
4. Rossouw JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007. PMID: 17405972
5. Mikkola TS, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause. 2015. PMID: 25803671
6. Casanova G, et al. Effects of nonoral estradiol–micronized progesterone or low-dose oral estradiol–drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause. Fertil Steril. 2009. PMID: 18706557
7. Canonico M, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007. PMID: 17309934
8. Canonico M, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008. PMID: 18495631
9. Smith NL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med. 2014. PMID: 24081194
10. Vinogradova Y, et al. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019. PMID: 30626577
11. Chlebowski RT, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020. PMID: 32721007
12. Fournier A, et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008. PMID: 17333341
13. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002. PMID: 12117397

---

Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario compounding pharmacy partner Trutina. To learn more or book a virtual consultation, visit manussolis.ca.